Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
​
Efficacy, safety and tolerability of an orally administered cannabis extractin the treatment of spasticity in patients with multiple sclerosis: arandomized, double-blind, placebo-controlled, crossover study
​
Smoked cannabis for spasticity in multiple sclerosis:a randomized, placebo-controlled trial
​
Sativex for the management of multiple sclerosis symptoms
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain